The headquarters of Wyeth Pharmaceuticals comprises 1.8 million square feet of office and lab space on a campus outside Philadelphia.
Shown here (left to right) are: Robert Ruffolo, Jr.; Frank Walsh; Bernard Poussot; Gary Stiles, MD; and Joseph Mahady.
People can’t write a sentence about Wyeth without starting with 'diet drug,'" moans Joseph Mahady, president of Wyeth Pharmaceuticals'
North American and global businesses. Yet he knows why the diet "cocktail" known as fen-phen—one part Pondimin (fenfluramine)
or Redux (dexfenfluramine) and one part generic phentermine—gets attention: "Where else have you seen a $16 billion block
taken from a company?" That's the amount drained from Wyeth during the last five years by fen-phen litigation—the costliest
product liability tort ever to hit a single pharma. (See "Balloon Mortgage.") What's more, the ongoing lawsuits have raised
a lingering cloud of uncertainty and suspicion that amplifies Wyeth's smallest mishap and obscures its genuine achievements.
What has Wyeth done to close this episode? Cynics may note the company changed its name two years ago from American Home Products.
But its makeover is profound. During the last decade, Wyeth has gone from a diversified company with consumer brands such
as Chef Boyardee and Pam and a reputation for "inventing the dry pipeline" into a focused pharma confident enough to pledge
to deliver an unprecedented two new molecular entities (NMEs) every year beginning in 2006 and "for many years thereafter,"
says CEO Robert Essner.
One reason for Wyeth's self-assurance: It successfully revamped how it does R&D. Drug research is notably iffy and expensive—roulette
with million-dollar chips—but questions about managing innovation vex executives everywhere: How do you catch lightning in
a bottle, keep scientists on schedule and under budget, wring more from less? Wyeth's answers may seem old fashioned but have
actually never gone out of style.
Wyeth wants to be "one of the most innovative companies in the industry," says Bernard Poussot, president of Wyeth Pharmaceuticals.
Chutzpah might not be the word this soft-spoken Frenchman would choose to describe its aspirations, but only a decade ago,
Wyeth "made pots and pans, shoe polish, Jiffy Pop—a great company store—but was nobody's idea of a real research company,"
Over the years, it has divested its crop protection and home foods businesses, exited the generic market, and broadened its
research capabilities. "We don't do just small molecules," says Frank Walsh, senior vice-president and head of discovery.
"We do biopharmaceuticals, and in another division, vaccines." Wyeth still makes consumer products and has a veterinary unit,
Fort Dodge Animal Health. But the pharmaceutical division accounts for 75 percent of sales.
The ninth largest pharma with $12.6 billion in 2003 pharmaceutical sales, Wyeth is often rumored to be shopping or targeted
for acquisition. But, Poussot says, "size is not really an obsession for us."
Wyeth is expert at neuroscience, vaccines, cardiovascular and metabolic disease, inflammation, oncology, and women's health.
It has five blockbusters in the market: antidepressant Effexor XR (venlafaxine), Enbrel (etanercept) for rheumatoid arthritis,
Protonix (pantroprazole) for heartburn, pediatric pneumonia vaccine Prevnar, and hormone replacement therapy Premarin (conjugated
Adding by Subtracting